Biotech & Pharma Day One readiness turns on the things a regulated medicines business cannot operate without for a single day: live manufacturing licenses, valid product registrations, and a working safety reporting system. Those set what has to be in place at close, and they tie back to the broader day one readiness a disciplined buyer plans across the deal.
A medicines business operates under good manufacturing practice authority, and that authority cannot lapse for a day. Establishment registrations, manufacturing licenses, and the inspected status of each site govern whether the business can make and release regulated product. A carve-out has to carry or re establish those so the Newco is authorized on Day One. A facility that loses its authorized standing cannot ship a single batch, no matter how full the warehouse is.
The buyer confirms each manufacturing site, testing laboratory, and warehouse is registered to the Newco and that its inspection history transfers cleanly. A change of ownership can require updated registrations and notifications to the agencies, and some markets treat the new owner as a fresh applicant. The buyer maps every site and its authorizations early, so authority is live before close rather than pending after it.
The quality system that supports release deserves specific attention. Batch records, the authorized person who releases product, validated equipment, and the quality management records all have to be live on the Newco's own footing at close. A separation that leaves the release process or its records on the seller's systems blocks the one step that turns finished goods into sellable product.
The buyer-side move is to treat GMP authority as a Day One must have with no tolerance for a gap. Registrations, licenses, inspected status, and the release process are each confirmed live before close. In pharma, the authority to make and release product is the license to operate, and Day One readiness depends on it.
Pharma revenue runs through product registrations, and those registrations do not move on their own. The marketing authorization holder in each market has to change to the Newco, and until that change is recognized the Newco may not be the lawful seller of the product. A carved-out portfolio can carry hundreds of registrations across dozens of markets, and each one is a separate transfer with its own agency and its own clock.
The buyer builds a registration inventory early and starts the highest value transfers first. Some agencies process a holder change in weeks, others in many months, and a few require local presence or a local representative before they will recognize the new holder. The buyer sequences the transfers by market value and by processing time, so the products that drive revenue are covered on Day One and the long markets are already in motion.
Labeling and artwork that name the holder deserve attention. Packaging often carries the holder name, the license number, and market specific text, and a change of holder can require updated artwork and stock. The buyer plans the artwork transition and any sell through of existing stock so the Newco does not face a market where it holds the registration but cannot lawfully label the box.
The buyer-side move is to treat product registrations as a Day One readiness item, not a market by market cleanup after close. Holder transfers, local representation, and labeling are each planned before close. In pharma, the registration is the right to sell, and Day One readiness protects it market by market.
The obligation to collect, assess, and report adverse events never pauses, including through a separation. Pharmacovigilance is a legal duty tied to every product on the market, and the Newco needs a qualified safety person, a live safety database, and working connections to the regulators on Day One. A gap in safety reporting is a regulatory breach that can put authorizations at risk, not an administrative delay.
The buyer confirms the safety organization, the case database, and the reporting links are live on the Newco's own footing at close, or covered by a clear transition arrangement with defined handover. The qualified person for pharmacovigilance, the safety master file, and the signal detection process all have to be in place. A separation that leaves cases routing to the seller's system, or leaves the qualified person role unfilled, exposes the Newco from the first day product is on the market.
Medical information and product complaints deserve attention alongside safety. The lines that patients and clinicians call, the complaint handling process, and the link from a complaint to a potential recall all have to function on Day One. A buyer that secures adverse event reporting but forgets medical information and complaints leaves a different part of the same duty exposed.
The buyer-side move is to treat pharmacovigilance as a gating Day One item with no acceptable gap. The safety database, the qualified person, the reporting links, and complaint handling are each confirmed before close. In medicines, the duty to patients runs continuously, and Day One readiness keeps it unbroken.
Many pharma businesses handle controlled substances, and the registrations that authorize that handling are owner specific and slow to transfer. The registration to manufacture, store, and distribute controlled drugs has to be live for the Newco before it can touch those products, and the agencies that grant it run on their own timelines. A carve-out that overlooks controlled substance authority can find a whole product line frozen on Day One.
The buyer maps every controlled substance registration, import and export authority, and secure storage requirement, and starts the transfers at signing because they are among the longest poles. The serialization and track and trace systems that prove a product is genuine also have to be live, with the Newco enrolled in the relevant verification network so its product is recognized at the pharmacy and the wholesaler.
The cold chain deserves specific attention for biologics and other temperature sensitive products. The qualified storage, the validated shipping lanes, and the monitoring that proves the product stayed in range all have to carry forward without a break. A separation that interrupts the cold chain or its monitoring records can render product unsellable and force a write off, even when nothing physically went wrong.
The buyer-side move is to treat controlled substance authority, serialization, and the cold chain as gating Day One items. Each registration, network enrollment, and validated lane is confirmed before close. In pharma logistics, the chain of custody and the chain of temperature both have to hold from the first day.
The pharma Day One readiness sequence respects that manufacturing authority, product registrations, safety reporting, and controlled substance handling all have to be live at close, and several of them run on agency timelines the deal cannot compress. A generic Day One plan treats these as quality items to settle after close. A pharma plan treats them as the gating conditions for making, selling, and standing behind the product at all.
Practically, the longest poles are the holder transfers in slow markets and the controlled substance registrations, and both start at signing. The buyer sequences the GMP registrations, the product transfers, the safety system stand-up, and the controlled substance and cold chain work so each is confirmed before Day One, with the agency dependent items started first because they take the longest to clear.
Governance has to include regulatory affairs, quality, and safety, not just IT and finance. The qualified person, the regulatory lead, and the safety lead hold the knowledge of what each agency requires and when. A governance structure that excludes them will set a close date the registrations or the safety system cannot support, and the gap surfaces only when the first batch cannot be released.
Biotech and pharma carve-outs reward buyers who respect the agency timelines and punish those who assume a close date can override them. Manufacturing authority cannot lapse. Registrations have to transfer. Safety reporting has to continue. Controlled substances and the cold chain have to hold. A buyer who plans Day One readiness around those truths operates from the first morning. A buyer who plans around an idealized timeline finds the product unsellable for want of a recognized holder.
A pharma business cannot make, release, or sell product without live manufacturing licenses, valid product registrations, and a working safety reporting system. Several of those run on regulator timelines the deal cannot compress. The buyer plans Day One readiness around the agency clock, not the deal's.
Manufacturing and establishment registrations authorize the site to make and release regulated product. A facility that loses its authorized status cannot ship a single batch. A change of ownership can require updated registrations, so the buyer confirms the site is authorized on its own footing before close.
Marketing authorizations and product registrations do not move on their own. The marketing authorization holder has to change to the Newco in each market, and until that transfer is recognized the Newco may not be the lawful seller. The buyer maps every registration and starts the transfers early.
The obligation to collect and report adverse events never pauses, including through a transition. The Newco needs a qualified safety person, a live safety database, and the connections to regulators working on Day One. A gap in safety reporting is a regulatory breach, not an administrative delay.
Where GMP, registrations, and supply govern a pharma carve-out exit.
Read the article →Where licensing, billing, and patient data govern a healthcare Day One.
Read the article →Where quality systems and registrations govern a device carve-out exit.
Read the article →The 90-day governance, IT, finance, HR and procurement separation plan we run on live carve-outs. Get the playbook plus the bi-weekly Day One Letter — short, signal-heavy, buyer-side.
No spam. Unsubscribe in one click. · Read the overview first →
Fixed-fee scope to make GMP authority, product registrations, pharmacovigilance, and the cold chain ready for Day One. Senior team on day one. The first conversation is always free.
Seven buyer-side moves to exit a Transition Services Agreement on time and below budget. The mark-up, the extension-fee curve, exit sequencing, and the 11-month calendar.
One tactic, one benchmark, or one pattern from a recent buyer-side engagement. Short. Signal heavy. Free.
Subscribe to The Day One Letter →A checklist without owners and sequence is a wish, not a plan. On a representative $48M-revenue carve-out, running ~200 Day-One line items across nine workstreams with named owners and explicit dependencies — rather than as a flat list — removes $2.1M of avoidable Day-One remediation cost.